Fig. 2: In vitro characteristics of NARA1leukin.
From: An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
a, b Sandwich ELISA coating anti-hIL-2 mAb 5344 (a) or hCD25 (b) and detecting with anti-hIL-2 mAb MAB202 shows binding of titrated hIL-2, hIL-2/NARA1 complexes, and NARA1leukin. c, d Phosphorylated STAT5 (pSTAT5) levels of human (c) and mouse (d) immune cell subsets responding to titrated hIL-2, hIL-2/NARA1 complexes, and NARA1leukin. 1:1 and 2:1 indicate molar ratios of cytokine to antibody of hIL-2/NARA1 complexes. Dotted lines indicate mean fluorescent intensity (MFI) of pSTAT5 of each cell subset following incubation in media for 15 min. Half maximal effective concentration (EC50) of each stimulant is presented in the table below. Differences between curves were analyzed using one-way ANOVA followed by Tukey’s multiple comparison test (c, d). (c) *p = 0.0112, **p = 0.0082, ****p < 0.0001, ***p = 0.0002. (d) ****p < 0.0001, ***p = 0.0001 (hIL-2), ***p = 0.0006 (hIL-2/NARA1). Data are presented as mean ± SD of two (a, b), four (c), or three (d) independent experiments. Source data are provided as a Source Data file.
